{"brief_title": "Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination", "brief_summary": "This multi-center, open-label study is designed to examine the effects on long-term glucose control and safety of AC2993 in patients with type 2 diabetes treated with metformin, sulfonylurea, or metformin and sulfonylurea combination.", "condition": "Diabetes Mellitus, Type 2", "intervention_type": "Drug", "intervention_name": "AC2993", "description": "Subjects will receive 5 \u03bcg AC2993, subcutaneously injected twice daily, for 4 weeks followed by 10 \u03bcg AC2993, subcutaneously injected twice daily, during a maintenance period that is expected to continue for at least 11 months.", "arm_group_label": "AC2993", "other_name": "synthetic exendin-4", "criteria": "Inclusion Criteria: - Subjects with type 2 diabetes - Treated for at least 3 months prior to screening either with metformin, sulfonylurea, or metformin and sulfonylurea combination - BMI 25-45 kg/m^2 - HbA1c between 7.5 % and 12.0 %, inclusive Exclusion Criteria: - Treated with other oral anti-diabetic agents other than metformin and sulfonylureas within 3 months of screening - Patients previously treated with AC2993 - Patients presently treated with insulin", "gender": "All", "minimum_age": "20 Years", "maximum_age": "75 Years", "healthy_volunteers": "No", "id": "NCT00044668.xml"}